ArticleInternational journal of chronic obstructive pulmonary disease2024

Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.

Michael Bogart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.